Deoxythymidine kinase in the staging of prostatic adenocarcinoma

✍ Scribed by Letocha, Henry; Eklöv, Solveig; Gronowitz, Simon; Norlén, Bo Johan; Nilsson, Sten

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 423 KB
• Volume: 29
• Category: Article
• ISSN: 0270-4137
• DOI: 10.1002/(sici)1097-0045(199607)29:1<15::aid-pros2>3.0.co;2-h

✦ Synopsis

The role of prostate-specific antigen in the management of prostatic adenocarcinoma is still not fully ascertained. Its place in the monitoring of patients who have undergone radical treatment is without question but its role in the primary assessment of a lesion is a point of continuous discussion.

This study reports the analysis of prostate-specific antigen (PSA) in 92 patients with different stages of prostatic adenocarcinoma prior to treatment; in the case of the localized lesions, this was based to a great extent on the findings at lymphadenectomy. Apart from PSA analysis, deoxythymidine kinase (dTK) analyses were also performed in an attempt to discover whether the latter could provide additional information about the tumor load in the different patient categories, viz. those with lymph node involvement (group l), those with lymph node involvement but without distant metastases (group 2), and those with disseminated disease (group 3).

The median PSA and dTK values in groups 1-3 were 6.5 pg/L and 2.7 U/pl, 16 pg/L and 2.6 U/pL, and 90 pg/L and 7.8 U/pL, respectively.

If the two analyses were used concomitantly, they could differentiate true localized disease from metastatic in approximately 92% of cases. The combination should prove of value in the primary assessment of a patient with a newly diagnosed prostatic adenocarcinoma.